Product Images Levetiracetam

This is a description of Levetiracetam Injection, USP which comes in a pack of 10 x 5mL vials each containing 500mg of Levetiracetam. It is for intravenous use only and must be diluted prior to administration. Each vial contains sodium acetate, sodium chloride and glacial acetic acid for pH adjustment. It is manufactured by Micro Labs Limited in India and manufactured for Micro Labs USA Inc. The storage temperature ranges between 25°C and 30°C.*

This is a chart showing the percentage of patients who received either a placebo or two different doses of Levetiracetam (1000mg/day or 3000mg/day) for an unspecified medical condition. The chart shows that the placebo group had a response rate of 37.1%, while the Levetiracetam group had response rates of 39.6% and 7.4% for the 1000mg/day and 3000mg/day doses, respectively.*

This is a graph showing the percentage of patients versus the dose of Levetiracetam, a medication commonly used to treat epilepsy. The graph also includes a percentage for a placebo group. The doses used in the study were 0, 1000, and 2000 mg/day. The graph shows that as the dose of Levetiracetam increases from 0 to 2000 mg/day, the percentage of patients decreases who experience seizures. The percentage of patients who experience seizures in the placebo group is not shown.*

This is a chart that shows the percentage of patients in a study group who received either a placebo or Levetiracetam 3000 mg/day. The study group had 104 patients. The chart shows that 35% of the patients received a placebo while the remaining patients received Levetiracetam 3000 mg/day. The percentage breakdown for patients receiving Levetiracetam is not available due to incomplete text obtained by .*

This appears to be a chart or graph showing the percentages of patients for different variables. The variables are not specified, but they range from 0% to 44.6%. There are two categories, labeled "Placebo" and "Levetiracetam," and the sample size for each category is given. Further information about the purpose or context of the chart is not available.*

This appears to be a table displaying the results of a medication study comparing placebo and Levetiracetam on patients, with percentages of patients displayed for different categories. However, without a clear indication of what the categories are, we cannot provide a more specific description.*

This appears to be a table showing the percentage of patients in a study who fall into different categories, possibly related to their response to a medication or treatment. The first column lists percentages in increments from 0% to 100%, while the second and third columns for the categories 45.2% and 72.2% are blank. The bottom two rows list two groups of patients - one who received a placebo (N=84), and the other who received a medication called Levetiracetam (N=79). The context and purpose of the study that produced these results is not provided.*

Levetiracetam is a medication available in the form of 500mg/5mL injection, USP for intravenous use only. It needs to be diluted before administration. The medication comes in a single-dose vial of 5mL and must be used only as directed. This text includes some batch details and artwork code numbers but lacks other essential information.*